Form D · Biotechnology
Ollin Biosciences, Inc.
Austin, TX · CIK 0002141184
Offering snapshot reported Jun 24, 2026 · SEC filing
- Reported sold
- $156M Offering amount: $330M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 14, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 24, 2026 | Initial | $156,249,990 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-588459
Source: Form D, filed Jun 24, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Berns | Director |
| Cariad Chester | Director |
| Fred Cohen | Director |
| Jason Coloma | Director |
| Jason Ehrlich | Director, Executive |
| Alaa Halawa | Director |
| Travis Murdoch | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1250 S. Capital Of Texas Hwy Building 3, Suite 400
Austin, TX, 78746
Austin, TX, 78746